论文部分内容阅读
目的探索免疫指标监测下进行个体化的有效肺动脉介入化疗。方法：自１９９７年１月至１９９９年１月， ３０例Ⅱ，Ⅳ期肺癌患者先予非根治住减负荷手术，继之以肺动脉介入化疗。于每疗程化疗前一天及化疗后三天取外周血检测血清白介素Ⅱ受体（ＳＩＬ－ⅡＲ）。随机分两组，监测组若化疗后比化疗前指标上升大于１０％，则于下一疗程化疗中更换化疗方案及调整药物剂量。对照组则按经验用药。结果：比较两组治疗前后 ＳＩＩ．－ⅡＲ均数的变化．两组的复发转移率及中位生存期，显示均具明显差异。结论：动态监测 ＳＩＩ－ⅡＲ的变化可有效地监测化疗的效果．并能及时地指导治疗．尽最大可能地确保每一化疗的有效性，并监测预后。这一方法对所有实体瘤的化疗均有借鉴作用。
Objective To explore the individualized effective pulmonary artery interventional chemotherapy under monitoring of immune indicators. METHODS: From January 1997 to January 1999, 30 patients with stage II and stage IV lung cancer were treated with non-radical steric relief followed by pulmonary artery interventional chemotherapy. Serum interleukin-II receptor (SIL-IIR) was measured in peripheral blood one day before chemotherapy and three days after chemotherapy. Randomly divided into two groups, if the monitoring group after chemotherapy than the pre-chemotherapy indicators increased by more than 10%, then in the next course of chemotherapy to replace the chemotherapy program and adjust the drug dose. The control group was administered empirically. Results: Compare the two groups before and after treatment SII. - Changes in the mean of the IIR. The recurrence metastasis rate and median survival time in both groups showed significant differences. Conclusion: Dynamic monitoring of SII-IIR changes can effectively monitor the effect of chemotherapy. And can promptly guide treatment. As much as possible to ensure the effectiveness of each chemotherapy, and monitor the prognosis. This method has implications for all solid tumors for chemotherapy.